Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow Jrheum on BlueSky
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleArticle

Vitamin D Receptor Polymorphism rs2228570 (Fok1) Is Associated with Rheumatoid Arthritis in North American Natives

CAROL A. HITCHON, YE SUN, DAVID B. ROBINSON, CHRISTINE A. PESCHKEN, CHARLES N. BERNSTEIN, KATHERINE A. SIMINOVITCH and HANI S. EL-GABALAWY
The Journal of Rheumatology September 2012, 39 (9) 1792-1797; DOI: https://doi.org/10.3899/jrheum.120387
CAROL A. HITCHON
From the Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba; Samuel Lunefeld Research Institute, Mount Sinai Hospital, Toronto, Ontario; Toronto General Research Institute, Mount Sinai Hospital, Toronto, Ontario; and Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: chitchon@hsc.mb.ca
YE SUN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DAVID B. ROBINSON
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHRISTINE A. PESCHKEN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHARLES N. BERNSTEIN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KATHERINE A. SIMINOVITCH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HANI S. EL-GABALAWY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
PreviousNext
Loading

Abstract

Objective. Vitamin D (VitD) has immunomodulatory activity relevant to rheumatoid arthritis (RA) and acts by binding nuclear receptors that regulate gene transcription. VitD receptor polymorphisms have been variably associated with RA. Because North American Native (NAN) populations have a high prevalence of RA with a strong genetic contribution, we studied potential associations of the rs2228570 (Fok1) VitD receptor polymorphism in a Canadian NAN population.

Methods. The single-nucleotide polymorphism (SNP) Fok1 was tested by sequencing NAN patients with RA (n = 448) and unrelated NAN controls (n = 704). Associations were tested using genotypic, dominant, and recessive models.

Results. The minor allele frequency (F/C) in the NAN control population was 0.44 and lower than reported in white subjects of the same geographical area. The Fok1 VitD receptor SNP was significantly associated with RA. Comparing patients with RA to unaffected NAN controls, the Fok1 SNP was associated with RA using both genotypic [FF vs Ff vs ff: RA 20%, 54%, 26% vs control 22%, 44%, 34% (chi-square 13.35, p = 0.003)] and dominant models [FF/Ff vs ff: RA 74% vs 26% control 66% vs 34% (OR 1.5, 95% CI 1.16–1.96, p = 0.003)]. This association was strongest in shared-epitope-positive RA.

Conclusion. VitD receptor polymorphisms may contribute to the high prevalence of RA in NAN populations.

Key Indexing Terms:
  • VITAMIN D RECEPTOR
  • SINGLE-NUCLEOTIDE POLYMORPHISM
  • RHEUMATOID
  • NORTH AMERICAN NATIVES

Vitamin D (VitD) has multiple effects on immune cell function, is important for normal host responses to infection, and influences bone metabolism and tumor proliferation. These mechanisms are all potentially important for the pathogenesis of inflammatory arthritis. The activity of 1,25 OH VitD is mediated through VitD nuclear receptors that, in complex with other nuclear proteins, regulate transcription of VitD-responsive genes1. VitD receptor binding sites are enriched in gene loci associated with autoimmunity and rheumatoid arthritis (RA)2. Both a deficiency of VitD and altered VitD receptor function have been variably linked to susceptibility to infection, malignancy, and autoimmune conditions including RA3,4,5. Several polymorphisms of the VitD receptor have been described. Only the Fok1 VitD receptor polymorphism has been associated with the development of RA in some populations6,7, while other polymorphisms may associate with early disease onset8 or activity9.

North American Native (NAN) populations have high RA prevalence rates, early onset of severe seropositive disease10, and a high frequency of HLA-DRB1 shared-epitope (SE) alleles in the background population11. Environmental factors associated with RA risk are also prevalent in this population, and population studies have documented low serum VitD levels in multiple North American populations including some NAN communities12,13.

We examined the association of the rs2228570 (Fok1) polymorphism of the VitD receptor gene with RA susceptibility in the NAN population of central Canada. The Fok1 F(C) allele was associated with RA in this NAN population, particularly in the setting of shared epitope.

MATERIALS AND METHODS

Subjects and procedures

Cree/Ojibway NAN patients with RA (n = 448) were recruited from clinic populations. All met American College of Rheumatology criteria for RA14. Cree/Ojibway controls (n = 704) were recruited from the same geographic areas. Controls were interviewed and examined by a rheumatologist (DBR or HSG) or trained research nurse and did not have clinical inflammatory arthritis or another autoimmune condition. All subjects had at least 3 of 4 grandparents of NAN origin (99% had 4 of 4) by self-report.

Blood samples were obtained at enrollment, stored at −80°C, and processed according to a standard procedure.

All study subjects provided informed consent. All aspects of the study were approved by the Research Ethics Board of the University of Manitoba and by the Band Councils of the study communities.

Rheumatoid factor (RF) and anticitrullinated protein antibodies (ACPA) testing

Blood samples were tested for RF by nephelometry or ELISA. Positive cutoffs were preset to be < 5% of a control white population (IgM RF > 50 IU/ml). Serum samples from RA patients and controls were tested for the presence of anticyclic citrullinated protein antibodies (ACPA) using a commercial anti-ACPA2 ELISA (Inova Diagnostics, San Diego, CA, USA).

HLA-DRB1 allele testing

HLA-DRB1 typing was performed by polymerase chain reaction using sequence-specific oligonucleotide primers in 353 patients with RA and 392 controls. The following DRB1 alleles were included as SE-bearing alleles: DRB1*0101, 0102, 0401, 0404, 0405, 0408, 0410, 1001, and 140211.

VitD receptor single-nucleotide polymorphism (SNP) testing

Genotyping was undertaken in the laboratory of Dr. Siminovitch. The multiplexed SNP assays were performed on the Sequenom Mass Array iPLEX platform (Sequenom, San Diego, CA, USA). Allele-specific extension products were plated onto a SpectroCHIP (Sequenom), subjected to mass spectrometric analysis, and the genotypes identified using SpectroCaller software (Sequenom). The VitD receptor gene is located on chromosome 12 (12q13.11). The Fok1 polymorphism is located at a translation initiation site in exon 2 at the 5’ gene region and is not in linkage disequilibrium with several other known VitD receptor polymorphisms located in noncoding introns and exon 9 at the 3’ gene region15.

Statistical analysis

Associations of VitD receptor gene polymorphisms and RA phenotype were analyzed using genotypic (FF vs Ff vs ff), allelic (F vs f), dominant (FF, Ff vs ff), and recessive (FF vs Ff, ff) models. Associations were tested by chi-square and regression methods using SPSS15. Attributable risk of Fok1 to RA was determined as the incidence of RA in the population with at least 1 dominant Fok1 allele minus the incidence of RA in the population without a dominant Fok1 allele16.

RESULTS

The clinical characteristics of subjects are shown in Table 1. As reported in this population, NAN have a high frequency of RF and ACPA-positive RA and there is a high frequency of RF and SE in the background population10,11. Patients with RA were older than the controls [mean 47 yrs (SD 15) vs 35 yrs (SD 12); p < 0.0001] and more likely to be female (82% vs 59%, respectively; p < 0.0001).

View this table:
  • View inline
  • View popup
Table 1.

Clinical characteristics of North American Native patients with rheumatoid arthritis (RA) and Native controls. Results are reported as percentage positive, mean (SD), or median (interquartile range; IQR) as indicated. All comparisons between RA and controls, p < 0.0001.

VitD receptor Fok1 polymorphism is associated with RA in NAN

The minor allele frequency (F/C) in the NAN control population was 0.44, similar to that of previous reports of Fok1 in the Manitoba NAN population (0.43)17, and the allele frequencies were in Hardy-Weinberg equilibrium. The observed minor allele frequency in NAN was lower than that reported in the Manitoba white population (0.64) and in other ethnic groups18,19,20. Comparing RA patients to unaffected NAN controls, the Fok1 SNP distribution was associated with RA using both genotypic [FF vs Ff vs ff: RA 20%, 54%, 26% vs control 22%, 44%, 34% (chi-square 13.35, p = 0.003)] and dominant models [FF/Ff vs ff: RA 74%, 26% vs control 66%, 34% (OR 1.5, 95% CI 1.16–1.96, p = 0.003; Table 2]. The FF or Ff genotype was more common in NAN patients with RA than in controls. No associations were seen with the allelic or recessive models.

View this table:
  • View inline
  • View popup
Table 2.

Vitamin D receptor single-nucleotide polymorphism rs2228570 (Fok1) is increased in North American Native patients with rheumatoid arthritis (RA) compared to unaffected Native controls. Values reported are n (% of RA or control); OR (95% CI).

Associations between RA and Fok1 were significant for SE-positive but not SE-negative subjects (Table 3), regardless of sex. This was seen for subjects with at least 1 copy of any SE allele in genotypic (FF vs Ff vs ff: chi-square 11.3, p = 0.003) and dominant models (FF or Ff vs ff: chi-square 9.8, p = 0.002), but not in recessive models. No additive or multiplicative interactions between SE and Fok1 were present in genotypic, dominant, or recessive models testing the association of Fok1 and RA. In multivariate binary logistic models controlling for age, sex, and SE, having at least 1 copy of the dominant Fok1 allele (FF or Ff) was independently associated with RA (OR 1.7, 95% CI 1.2–2.5, p = 0.002). The attributable risk of having at least 1 copy of the dominant Fok1 allele for RA in this NAN population was 0.098 (10%). In the NAN subset population with at least 1 copy of SE, the attributable risk was 0.084 (8%). In contrast, the attributable risk of at least 1 copy of SE to RA in this population was 0.22 (22%).

View this table:
  • View inline
  • View popup
Table 3.

Vitamin D receptor single-nucleotide polymorphism rs2228570 (Fok1) and shared-epitope (SE) status in patients with rheumatoid arthritis (RA) and controls. Values reported are n (% of RA or control); OR (95% CI).

Small sample size reduced the power of the study to detect significant associations of SE alleles and Fok1. In this population (both controls and patients with RA), the presence of any SE allele was associated with the Fok1 allele in genotypic (ff/SE-negative 46/169, Ff/SE-negative 90/169, FF/SE-negative 33/169 vs ff/SE-positive 202/576, Ff/SE-positive 247/576, FF/SE-positive 127/576; chi-square 5.9, p = 0.052) but not dominant models (ff/SE-negative 46/169, Ff or FF/SE-negative 123/169 vs ff/SE-positive 202/576, FF or Ff/SE-positive 374/576; chi-square 3.6, p = 0.06). A modest association was found between having at least 1 copy of the HLA-DRB1*0101 SE allele and Fok1 receptor status (using the dominant model) in the entire study population (RA and controls: ff/HLA*0101-negative 195/662 vs FF or Ff/HLA*0101-positive 29/51; chi-square 4.2, p = 0.04, without correction for multiple comparisons), but not in the subset that had at least 1 copy of any SE allele (ff/HLA*0101-negative 159/503 vs FF or Ff/HLA* 0101-positive 29/51; chi-square 2.8, p = 0.09). The presence of 2 copies of DRB1*1402 was associated with the Fok1 allele using the dominant model (chi-square 6.1, p < 0.05, without correction for multiple comparisons; Table 4).

View this table:
  • View inline
  • View popup
Table 4.

Associations between individual HLA-DRB1 shared-epitope (SE) alleles and Fok1 polymorphisms in the North American Native (NAN) population including patients and controls, and the subset of NAN with at least 1 HLA-DRB1 SE allele.

VitD receptor polymorphisms were not associated with RF or ACPA positivity in NAN patients with RA. However, in NAN controls with the SE, Fok1 was associated with RF: 14/18 (78%) FF, 18/31 (58%) Ff, and 23/61 (38%) ff were positive for RF (chi-square 10, p = 0.007) and 32/49 (65%) subjects with FF or Ff were positive for RF compared to 23/61 (38%) subjects with ff (chi-square 8.3, p = 0.004). No associations were seen with ACPA in NAN controls.

DISCUSSION

The VitD receptor Fok1 polymorphism was shown to be associated with RA in our NAN study population. Compared to the NAN control population, NAN patients with RA were more likely to be homozygous or heterozygous for the F(C) allele. Previous studies in white populations have also shown an association with the F(C) allele and RA, and that this association may be strongest for individuals with HLA-DRB1 SE alleles6. The frequency of the Fok1 F(C) allele in our NAN control population was lower than that reported in unaffected white subjects from the same geographical area (0.64)17 and other European21 and African American (0.78)22 populations.

Polymorphisms at the Fok1 site, located in a coding exon at the 5’ region of the VitD receptor gene, result in different protein structures. The Fok1 f(T) allele encodes a 427-amino acid receptor, and has been variably associated with an increased risk of several malignancies, especially in the context of environmental factors23,24. The F(C) allele encodes a smaller (424 amino acids) possibly more active protein product25 that appears to be associated with greater bone mineral density. However, NAN have lower site-specific bone mineral density26 and low serum VitD compared to whites27. The biological effects of the Fok1 VitD receptor polymorphisms may differ across VitD-responsive genes and cell types and may be influenced by serum VitD levels and other VitD receptor polymorphisms18,23.

Other VitD receptor polymorphisms have been identified in the promoter, exons 2–9, introns, and the 3’ region of the gene23 and were initially identified using restriction enzymes. Bsm, Apa1, EcoRV, and Tru9I restriction fragment length polymorphisms (RFLP) are located in noncoding introns at the 3’ region of the VitD receptor gene. Taq1 is located in exon 9, also at the 3’ region. These polymorphisms (Bsm1, Apa1, EcoRV, Tru91, and Taq1) are in linkage disequilibrium with each other, but not with Fok1. The Cdx2 polymorphism is located in the 5’ promotor region. To date, no functional consequences of these RFLP have been reported, although they may affect RNA stability and thus gene expression21.

The Bsm1, Taq1, and Apa1 VitD receptor RFLP have been studied in RA6,28. While no clear associations with disease prevalence have been demonstrated, there are suggestions that these RFLP may influence disease characteristics. In a Spanish population, although no differences in the distribution of RFLP between patients with RA and controls were observed, the combination of homozygous absence of Bsm1 and presence of Taq1 was associated with slightly earlier onset of RA, particularly for SE-positive women8. A separate study reported an association between Bsm1 RFLP and RA disease activity9. Multiple polymorphisms may influence disease features or susceptibility21. Further genotyping studies are planned to investigate the association of Fok1 and other VitD receptor polymorphisms in RA.

VitD is a key regulator of immune responses and has potent pro- and antiinflammatory effects on multiple immune cells1. Although the mechanisms for these effects are not fully understood, excess VitD receptor activity might evoke more robust innate immune responses to bacteria, resulting in a greater potential to break self-tolerance. Increased activity of this receptor may also alter the balance between immunostimulatory and immunoregulatory cells. RF titers have been shown to correlate modestly with immune responses to common pathogens in early inflammatory arthritis29, and in NAN controls with the SE, Fok1 appeared to associate with RF, possibly reflecting exposure to pathogens. In contrast, low serum levels of VitD have been associated with RA activity30 and with increased risk of developing RA in some but not all studies, and animal models suggest a functioning VitD receptor is important to limit synovial inflammation31.

Genome-wide association studies (GWAS) conducted primarily in whites of European descent have identified the HLA-DRB1 locus as the most significant genetic contributor to RA disease risk, although several other loci with lower contributions have been identified32,33. While no study has identified a specific association with the VitD receptor gene locus, an association with chromosome 12q13 and RA in the setting of HLA SE34,35 is interesting. The VitD receptor gene is located in this region36, as are the genes for small ubiquitin-like modifier 1-specific protease (SENP1; 12.13.1q), which influences expression of matrix metalloproteinase-1 in RA synoviocytes37 and collagen type 2 (COL2a; 12.13.1–13.2), although the latter was found not to be associated with RA in a small study38. Thus, the observed associations of Fok1 and RA may be due to linkage disequilibrium with other RA-associated genes.

Our finding of an association between the Fok1 F allele and disease risk primarily in SE-positive individuals, while potentially related to the low numbers of SE-negative subjects in this population, also raises the possibility that the autoimmune effects of the variant VitD receptor are enhanced against the background of SE positivity. This is supported by studies of RA family trios in which F(C) transmission was enhanced in the setting of the SE6. VitD receptor polymorphisms have also been shown to cosegregate with disease-specific HLA-DRB1 alleles in other autoimmune conditions such as multiple sclerosis39. In addition, binding sites for the VitD receptor have been found in gene regions associated with autoimmune disease2. Further studies are required to explore this hypothesis, to evaluate the extent to which the polymorphism correlates with VitD levels and function in both f/f homozygotes and F/f heterozygotes, and thereby to delineate the pathway linking this polymorphism to increased risk for RA in the NAN population12.

The association of Fok1 and RA observed in this population requires validation in a separate NAN population, preferably of Cree/Ojibway descent.

Acknowledgment

The authors thank the Assembly of Manitoba Chiefs and the Chiefs and Band Councils of the Norway House and St. Theresa Point communities for their role in facilitating this study. We also thank Donna Hart, RN, for assistance with the study and Drs. Kiem Oen (University of Manitoba, Winnipeg, Manitoba) and Janet Markland (University of Saskatchewan, Saskatoon, Saskatchewan) for assistance with subject recruitment.

Footnotes

  • Supported in part by funding from the Canadian Institutes of Health Research (MOP7770 and IIN 84040). Prof. Siminovitch is supported by a Canada Research Chair and holds the Sherman Family Chair in Genomic Medicine.

  • Accepted for publication May 28, 2012.

REFERENCES

  1. 1.↵
    1. Di Rosa M,
    2. Malaguarnera M,
    3. Nicoletti F,
    4. Malaguarnera L
    . Vitamin D3: A helpful immunomodulator. Immunology 2011;134:123–39.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Ramagopalan SV,
    2. Heger A,
    3. Berlanga AJ,
    4. Maugeri NJ,
    5. Lincoln MR,
    6. Burrell A,
    7. et al.
    A ChIP-seq defined genome-wide map of vitamin D receptor binding: Associations with disease and evolution. Genome Res 2010;20:1352–60.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Hewison M
    . An update on vitamin D and human immunity. Clin Endocrinol 2012;76:315–25.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Cutolo M,
    2. Pizzorni C,
    3. Sulli A
    . Vitamin D endocrine system involvement in autoimmune rheumatic diseases. Autoimmun Rev 2011;11:84–7.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Fleet JC,
    2. Desmet M,
    3. Johnson R,
    4. Li Y
    . Vitamin D and cancer: A review of molecular mechanisms. Biochem J 2012;441:61–76.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Maalej A,
    2. Petit-Teixeira E,
    3. Michou L,
    4. Rebai A,
    5. Cornelis F,
    6. Ayadi H
    . Association study of VDR gene with rheumatoid arthritis in the French population. Genes Immun 2005;6:707–11.
    OpenUrlPubMed
  7. 7.↵
    1. Karray EF,
    2. Ben Dhifallah I,
    3. Ben Abdelghani K,
    4. Ben Ghorbel I,
    5. Khanfir M,
    6. Houman H,
    7. et al.
    Associations of vitamin D receptor gene polymorphisms FokI and BsmI with susceptibility to rheumatoid arthritis and Behcet’s disease in Tunisians. Joint Bone Spine 2012;79:144–8.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Garcia-Lozano JR,
    2. Gonzalez-Escribano MF,
    3. Valenzuela A,
    4. Garcia A,
    5. Nunez-Roldan A
    . Association of vitamin D receptor genotypes with early onset rheumatoid arthritis. Eur J Immunogenet 2001;28:89–93.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Gomez-Vaquero C,
    2. Fiter J,
    3. Enjuanes A,
    4. Nogues X,
    5. Diez-Perez A,
    6. Nolla JM
    . Influence of the BsmI polymorphism of the vitamin D receptor gene on rheumatoid arthritis clinical activity. J Rheumatol 2007;34:1823–6.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Peschken CA,
    2. Hitchon CA,
    3. Robinson DB,
    4. Smolik I,
    5. Barnabe CR,
    6. Prematilake S,
    7. et al.
    Rheumatoid arthritis in a North American Native population: Longitudinal followup and comparison with a white population. J Rheumatol 2010;37:1589–95.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. El-Gabalawy HS,
    2. Robinson DB,
    3. Hart D,
    4. Elias B,
    5. Markland J,
    6. Peschken CA,
    7. et al.
    Immunogenetic risks of anti-cyclical citrullinated peptide antibodies in a North American Native population with rheumatoid arthritis and their first-degree relatives. J Rheumatol 2009;36:1130–5.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Lebrun JB,
    2. Moffatt ME,
    3. Mundy RJ,
    4. Sangster RK,
    5. Postl BD,
    6. Dooley JP,
    7. et al.
    Vitamin D deficiency in a Manitoba community. Can J Public Health 1993;84:394–6.
    OpenUrlPubMed
  13. 13.↵
    1. Holick MF
    . Vitamin D deficiency. N Engl J Med 2007;357:266–81.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Arnett FC,
    2. Edworthy SM,
    3. Bloch DA,
    4. McShane DJ,
    5. Fries JF,
    6. Cooper NS,
    7. et al.
    The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Nejentsev S,
    2. Godfrey L,
    3. Snook H,
    4. Rance H,
    5. Nutland S,
    6. Walker NM,
    7. et al.
    Comparative high-resolution analysis of linkage disequilibrium and tag single nucleotide polymorphisms between populations in the vitamin D receptor gene. Hum Mol Genet 2004;13:1633–9.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Fletcher RW,
    2. Fletcher SW
    . Clinical epidemiology: the essentials. 2nd ed. Baltimore: Williams and Wilkins; 1988.
  17. 17.↵
    1. Larcombe LA,
    2. Orr PH,
    3. Lodge AM,
    4. Brown JS,
    5. Dembinski IJ,
    6. Milligan LC,
    7. et al.
    Functional gene polymorphisms in Canadian aboriginal populations with high rates of tuberculosis. J Infect Dis 2008;198:1175–9.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Whitfield GK,
    2. Remus LS,
    3. Jurutka PW,
    4. Zitzer H,
    5. Oza AK,
    6. Dang HT,
    7. et al.
    Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene. Mol Cell Endocrinol 2001;177:145–59.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Gennari L,
    2. Becherini L,
    3. Mansani R,
    4. Masi L,
    5. Falchetti A,
    6. Morelli A,
    7. et al.
    FokI polymorphism at translation initiation site of the vitamin D receptor gene predicts bone mineral density and vertebral fractures in postmenopausal Italian women. J Bone Miner Res 1999;14:1379–86.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Eccleshall TR,
    2. Garnero P,
    3. Gross C,
    4. Delmas PD,
    5. Feldman D
    . Lack of correlation between start codon polymorphism of the vitamin D receptor gene and bone mineral density in premenopausal French women: The OFELY study. J Bone Miner Res 1998;13:31–5.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Uitterlinden AG,
    2. Fang Y,
    3. Van Meurs JB,
    4. Pols HA,
    5. Van Leeuwen JP
    . Genetics and biology of vitamin D receptor polymorphisms. Gene 2004;338:143–56.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Harris SS,
    2. Eccleshall TR,
    3. Gross C,
    4. Dawson-Hughes B,
    5. Feldman D
    . The vitamin D receptor start codon polymorphism (FokI) and bone mineral density in premenopausal American black and white women. J Bone Miner Res 1997;12:1043–8.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Kostner K,
    2. Denzer N,
    3. Muller CS,
    4. Klein R,
    5. Tilgen W,
    6. Reichrath J
    . The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: A review of the literature. Anticancer Res 2009;29:3511–36.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Tang C,
    2. Chen N,
    3. Wu M,
    4. Yuan H,
    5. Du Y
    . Fok1 polymorphism of vitamin D receptor gene contributes to breast cancer susceptibility: A meta-analysis. Breast Cancer Res Treat 2009;117:391–9.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Arai H,
    2. Miyamoto K,
    3. Taketani Y,
    4. Yamamoto H,
    5. Iemori Y,
    6. Morita K,
    7. et al.
    A vitamin D receptor gene polymorphism in the translation initiation codon: Effect on protein activity and relation to bone mineral density in Japanese women. J Bone Miner Res 1997;12:915–21.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Leslie WD,
    2. Metge CJ,
    3. Weiler HA,
    4. Doupe M,
    5. Wood SP,
    6. O’Neil JD
    . Bone density and bone area in Canadian Aboriginal women: The First Nations Bone Health Study. Osteoporos Int 2006;17:1755–62.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Weiler HA,
    2. Leslie WD,
    3. Krahn J,
    4. Steiman PW,
    5. Metge CJ
    . Canadian Aboriginal women have a higher prevalence of vitamin D deficiency than non-Aboriginal women despite similar dietary vitamin D intakes. J Nutr 2007;137:461–5.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Lee YH,
    2. Bae SC,
    3. Choi SJ,
    4. Ji JD,
    5. Song GG
    . Associations between vitamin D receptor polymorphisms and susceptibility to rheumatoid arthritis and systemic lupus erythematosus: A meta-analysis. Mol Biol Rep 2011;38:3643–51.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Newkirk MM,
    2. Goldbach-Mansky R,
    3. Senior BW,
    4. Klippel J,
    5. Schumacher HR Jr.,
    6. El-Gabalawy HS
    . Elevated levels of IgM and IgA antibodies to Proteus mirabilis and IgM antibodies to Escherichia coli are associated with early rheumatoid factor (RF)-positive rheumatoid arthritis. Rheumatology 2005;44:1433–41.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Patel S,
    2. Farragher T,
    3. Berry J,
    4. Bunn D,
    5. Silman A,
    6. Symmons D
    . Association between serum vitamin D metabolite levels and disease activity in patients with early inflammatory polyarthritis. Arthritis Rheum 2007;56:2143–9.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Zwerina K,
    2. Baum W,
    3. Axmann R,
    4. Heiland GR,
    5. Distler JH,
    6. Smolen J,
    7. et al.
    Vitamin D receptor regulates TNF-mediated arthritis. Ann Rheum Dis 2011;70:1122–9.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Gregersen PK
    . Susceptibility genes for rheumatoid arthritis — A rapidly expanding harvest. Bull NYU Hosp Jt Dis 2010;68:179–82.
    OpenUrlPubMed
  33. 33.↵
    1. Okada Y,
    2. Terao C,
    3. Ikari K,
    4. Kochi Y,
    5. Ohmura K,
    6. Suzuki A,
    7. et al.
    Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the Japanese population. Nat Genet 2012;44:511–6.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Osorio YF,
    2. Bukulmez H,
    3. Petit-Teixeira E,
    4. Michou L,
    5. Pierlot C,
    6. Cailleau-Moindrault S,
    7. et al.
    Dense genome-wide linkage analysis of rheumatoid arthritis, including covariates. Arthritis Rheum 2004;50:2757–65.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Barton A,
    2. Thomson W,
    3. Ke X,
    4. Eyre S,
    5. Hinks A,
    6. Bowes J,
    7. et al.
    Rheumatoid arthritis susceptibility loci at chromosomes 10p15, 12q13 and 22q13. Nat Genet 2008;40:1156–9.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Labuda M,
    2. Fujiwara TM,
    3. Ross MV,
    4. Morgan K,
    5. Garcia-Heras J,
    6. Ledbetter DH,
    7. et al.
    Two hereditary defects related to vitamin D metabolism map to the same region of human chromosome 12q 13–14. J Bone Miner Res 1992;7:1447–53.
    OpenUrlPubMed
  37. 37.↵
    1. Maciejewska-Rodrigues H,
    2. Karouzakis E,
    3. Strietholt S,
    4. Hemmatazad H,
    5. Neidhart M,
    6. Ospelt C,
    7. et al.
    Epigenetics and rheumatoid arthritis: The role of SENP1 in the regulation of MMP-1 expression. J Autoimmun 2010;35:15–22.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Pile KD,
    2. Wordsworth BP
    . Susceptibility to rheumatoid arthritis is not associated with a single common allele of the type 2 collagen gene (COL2A1). Br J Rheumatol 1993;32:456–7.
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    1. Niino M,
    2. Fukazawa T,
    3. Yabe I,
    4. Kikuchi S,
    5. Sasaki H,
    6. Tashiro K
    . Vitamin D receptor gene polymorphism in multiple sclerosis and the association with HLA class II alleles. J Neurol Sci 2000;177:65–71.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 39, Issue 9
1 Sep 2012
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Vitamin D Receptor Polymorphism rs2228570 (Fok1) Is Associated with Rheumatoid Arthritis in North American Natives
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Vitamin D Receptor Polymorphism rs2228570 (Fok1) Is Associated with Rheumatoid Arthritis in North American Natives
CAROL A. HITCHON, YE SUN, DAVID B. ROBINSON, CHRISTINE A. PESCHKEN, CHARLES N. BERNSTEIN, KATHERINE A. SIMINOVITCH, HANI S. EL-GABALAWY
The Journal of Rheumatology Sep 2012, 39 (9) 1792-1797; DOI: 10.3899/jrheum.120387

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Vitamin D Receptor Polymorphism rs2228570 (Fok1) Is Associated with Rheumatoid Arthritis in North American Natives
CAROL A. HITCHON, YE SUN, DAVID B. ROBINSON, CHRISTINE A. PESCHKEN, CHARLES N. BERNSTEIN, KATHERINE A. SIMINOVITCH, HANI S. EL-GABALAWY
The Journal of Rheumatology Sep 2012, 39 (9) 1792-1797; DOI: 10.3899/jrheum.120387
del.icio.us logo Twitter logo Facebook logo  logo Mendeley logo
  • Tweet Widget
  •  logo
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgment
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Antinuclear Antibody Multiplex Utilization Across a Large Federal Hospital System: An Investigation of Ordering Practices and Rheumatologic Outcomes
  • Canadian Rheumatology Association Annual Scientific Meeting TELUS Convention Centre Calgary, Alberta, Canada February 26–March 1, 2025
  • Achievement and Usefulness of Intermediate Treatment Targets for Still Disease Proposed by the European Alliance of Associations for Rheumatology and the Paediatric Rheumatology European Society
Show more Articles

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2025 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire